Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | EPOR | P19235 | 5/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15448254 | 1.00 | ALDH1A1 (0.47) | ALDH1A1KMT2ATDP1L3MBTL1MAPK1 | |
| SCHEMBL10315706 | 1.00 | ALDH1A1 (0.47) | ALDH1A1KMT2ATDP1L3MBTL1MAPK1 | |
| SCHEMBL20858214 | 0.88 | EPOR (0.49) | ALDH1A1KMT2ATDP1L3MBTL1MAPK1 | |
| SCHEMBL2059549 | 0.87 | CTRB1 (0.49) | ALDH1A1KMT2ATDP1L3MBTL1MAPK1 | |
| SCHEMBL7438541 | 0.87 | CTRB1 (0.49) | ALDH1A1KMT2ATDP1L3MBTL1MAPK1 | |
| SCHEMBL12619862 | 0.86 | ALDH1A1 (0.45) | ALDH1A1KMT2ATDP1L3MBTL1MAPK1 | |
| SCHEMBL842166 | 0.86 | ALDH1A1 (0.50) | ALDH1A1KMT2ATDP1L3MBTL1MAPK1 | |
| SCHEMBL13064940 | 0.86 | L3MBTL1 (0.52) | ALDH1A1KMT2AL3MBTL1EPORGAA | |
| SCHEMBL824998 | 0.86 | ALDH1A1 (0.50) | ALDH1A1KMT2ATDP1L3MBTL1MAPK1 | |
| SCHEMBL634623 | 0.86 | ALDH1A1 (0.50) | ALDH1A1KMT2ATDP1L3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140018549-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018549-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-8450336-B2 | Use of D-serine derivatives for the treatment of anxiety disorders | NPS PHARMACEUTICALS, INC (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450336-B2 | Use of D-serine derivatives for the treatment of anxiety disorders | NPS PHARMACEUTICALS, INC (US) | 2013-05-28 | — | — | US | disclosed |
| US-7902401-B2 | Fluorinated compounds | NPS PHARMACEUTICALS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902401-B2 | Fluorinated compounds | NPS PHARMACEUTICALS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100016403-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | NPS PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20100016403-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | NPS PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20090005433-A1 | Fluorinated Compounds | NPS PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20090005433-A1 | Fluorinated Compounds | NPS PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| WO-2008070994-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | NPS PHARMACEUTICALS, INC. (CA) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007076306-A1 | FLUORINATED COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005433-A1 | Fluorinated Compounds | CNR1, NPFFR1, AFF1 | ALDH1A1 1176/4885KMT2A 1301/4885TDP1 208/4885 |
| US-20140018549-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | OXSR1, SRR, GLRB | ALDH1A1 1332/4885KMT2A 4045/4885TDP1 4094/4885 |
| US-20100016403-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | OXSR1, SRR, GLRB | ALDH1A1 1317/4885KMT2A 4073/4885TDP1 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.